MÜLLER, R.-U.; LIANNE MESSCHENDORP, A.; BIRN, H.; CAPASSO, G.; CORNEC-LE GALL, E.; DEVUYST, O.; EERDE, A. van; GUIRCHOUN, P.; HARRIS, T.; HOORN, E. J.; KNOERS, N. V.; KORST, U.; MEKAHLI, D.; LE MEUR, Y.; NIJENHUIS, T.; ONG, A. C.; SAYER, J. A.; SCHAEFER, F.; SERVAIS, A.; TESAR, V.; TORRA, R.; GANSEVOORT, S. B. W. and R. T. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. KIDNEYS, [S. l.], v. 11, n. 1, p. 37–39, 2022. DOI: 10.22141/2307-1257.11.1.2022.357. Disponível em: https://kidneys.zaslavsky.com.ua/index.php/journal/article/view/357. Acesso em: 8 aug. 2022.